JP2016537369A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537369A5
JP2016537369A5 JP2016531646A JP2016531646A JP2016537369A5 JP 2016537369 A5 JP2016537369 A5 JP 2016537369A5 JP 2016531646 A JP2016531646 A JP 2016531646A JP 2016531646 A JP2016531646 A JP 2016531646A JP 2016537369 A5 JP2016537369 A5 JP 2016537369A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently selected
heterocyclyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537369A (ja
JP6494624B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065594 external-priority patent/WO2015073763A1/en
Publication of JP2016537369A publication Critical patent/JP2016537369A/ja
Publication of JP2016537369A5 publication Critical patent/JP2016537369A5/ja
Application granted granted Critical
Publication of JP6494624B2 publication Critical patent/JP6494624B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016531646A 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体 Expired - Fee Related JP6494624B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14
US61/904,116 2013-11-14
PCT/US2014/065594 WO2015073763A1 (en) 2013-11-14 2014-11-14 Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors

Publications (3)

Publication Number Publication Date
JP2016537369A JP2016537369A (ja) 2016-12-01
JP2016537369A5 true JP2016537369A5 (OSRAM) 2017-12-21
JP6494624B2 JP6494624B2 (ja) 2019-04-03

Family

ID=51952052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016531646A Expired - Fee Related JP6494624B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
JP2016531020A Expired - Fee Related JP6494622B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016531020A Expired - Fee Related JP6494622B2 (ja) 2013-11-14 2014-11-14 カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体

Country Status (9)

Country Link
US (3) US9598423B2 (OSRAM)
EP (2) EP3068785B1 (OSRAM)
JP (2) JP6494624B2 (OSRAM)
CN (2) CN105916855B (OSRAM)
AR (1) AR098414A1 (OSRAM)
ES (2) ES2718218T3 (OSRAM)
TW (1) TW201605859A (OSRAM)
UY (1) UY35834A (OSRAM)
WO (2) WO2015073767A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
WO2015129821A1 (ja) * 2014-02-27 2015-09-03 国立大学法人東京大学 オートタキシン阻害活性を有する縮合ピラゾール誘導体
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
EP3458455B1 (en) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018011163A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
MX2019003425A (es) 2016-09-28 2019-08-16 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos.
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
CA3070004A1 (en) * 2017-07-27 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレーターとしての架橋二環化合物
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) * 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
JP7090958B2 (ja) * 2018-06-01 2022-06-27 アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性csf1r阻害薬化合物
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
CN112955142A (zh) 2018-09-21 2021-06-11 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
EP3909583A4 (en) 2019-01-11 2022-08-17 Shionogi & Co., Ltd DIHYDROPYRAZOLOPYRAZINONE DERIVATIVES WITH MGAT2 INHIBITORY ACTIVITY
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
US20220081446A1 (en) * 2019-01-25 2022-03-17 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of 1,2,3-triazolo[1,5-a]pyrazines derivative and preparation method for crystal form
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
JP2023541465A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
WO2022166778A1 (zh) * 2021-02-04 2022-08-11 江苏恒瑞医药股份有限公司 一种衣壳蛋白抑制剂的药物组合物及其制备方法
US20250188075A1 (en) * 2022-01-27 2025-06-12 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
EP4538275A1 (en) * 2022-06-13 2025-04-16 Shionogi & Co., Ltd Crystal of dihydropyridinone derivative or solvate thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
AU2004303826A1 (en) * 2003-12-11 2005-07-07 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I Epsilon
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JP6010557B2 (ja) 2011-03-02 2016-10-19 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換トリアジン誘導体
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Similar Documents

Publication Publication Date Title
JP2016537369A5 (OSRAM)
JP2016537366A5 (OSRAM)
JP2016507502A5 (OSRAM)
JP6474068B2 (ja) 2−アミノピリミジン系化合物およびその薬物組成物と使用
JP2017518344A5 (OSRAM)
JP2013532652A5 (OSRAM)
TN2020000195A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
JP2019094345A5 (OSRAM)
JP2017501237A5 (OSRAM)
JP2014513139A5 (OSRAM)
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
JP2016515561A5 (OSRAM)
JP2016508135A5 (OSRAM)
JP2015520140A5 (OSRAM)
JP2008523041A5 (OSRAM)
HRP20210447T1 (hr) Piridinski spoj
JP2016515560A5 (OSRAM)
JP2014500295A5 (OSRAM)
JP2014506582A5 (OSRAM)
JP2012532112A5 (OSRAM)
JP2013533879A5 (OSRAM)
JP2016517857A5 (OSRAM)
JP2015523390A5 (OSRAM)
JP2016531868A5 (OSRAM)
RU2010143455A (ru) Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов